iShares Gold Trust vs Illumina, Inc. — how do they compare? iShares Gold Trust trades at $83.02, while Illumina, Inc. trades at $190.81 (market cap $29.12B). The key difference: Illumina, Inc. is trading nearer its 52-week high, iShares Gold Trust nearer its low. Which is the better fit depends on your goals.
| IAU | ILMN | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Health |
52-Week High | $101.57 | $205.10 |
52-Week Low | $62.49 | $91.00 |
Market Cap | — | $29.12B |
Enterprise Value | — | $30.48B |
Signals from Pluang's Aura AI — not financial advice
IAU (iShares Gold Trust) trades at $82.76, up 0.3% on the day, with technical indicators showing mixed signals - a bullish moving average trend but overbought RSI levels. The ETF benefits from gold's recent momentum as inflation data aligns with expectations and geopolitical tensions boost safe-haven demand. Recent news highlights gold's strong performance with spot prices reaching $4,438/oz following July CPI data.
The outlook remains positive given gold's defensive characteristics amid economic uncertainty, though overbought technical conditions suggest potential near-term consolidation. Key risks include Federal Reserve policy shifts and dollar strength, while institutional buying and central bank demand provide underlying support.
Illumina (ILMN) trades at $191.32, down 0.25% on the day, with a bullish earnings trend after beating Q2 2026 estimates. The stock shows strong profitability with a net margin of 18.34% and positive cash flow, though technical indicators signal near-term bearish pressure. Recent news highlights institutional buying and AI partnerships boosting growth prospects.
Outlook remains positive with a consensus price target of $201.58, offering ~5% upside, supported by solid fundamentals and analyst optimism. Risks include high valuation multiples and competitive pressures in genomics. The stock presents a growth opportunity with manageable near-term volatility.
Trailing returns across standard periods
IAU is a physically backed ETF that seeks to reflect the performance of the price of gold. It provides a convenient and liquid way for investors to include gold in their portfolios as a potential hedge.
Read more on IAU →Illumina provides tools and services to analyze genetic material with life science and clinical lab applications. The company generates over 90% of its revenue from sequencing instruments, consumables, and services. Illumina's high-throughput technology enables whole genome sequencing in humans and other large organisms. Its lower throughput tools enable applications that require smaller data outputs, such as viral and cancer tumor screening. Illumina also sells microarrays (less than 10% of sales) that enable lower-cost, focused genetic screening with primarily consumer and agricultural applications.
Read more on ILMN →